KLP Kapitalforvaltning AS Sells 100 Shares of Humana Inc. (NYSE:HUM)

KLP Kapitalforvaltning AS lowered its holdings in shares of Humana Inc. (NYSE:HUM) by 0.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,670 shares of the insurance provider’s stock after selling 100 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Humana were worth $11,057,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of HUM. denkapparat Operations GmbH purchased a new position in Humana during the 4th quarter valued at about $323,000. Allstate Corp acquired a new stake in Humana in the 4th quarter worth approximately $905,000. Deutsche Bank AG boosted its stake in Humana by 18.2% in the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider’s stock worth $160,185,000 after purchasing an additional 97,071 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Humana in the 1st quarter worth approximately $1,309,000. Finally, Fred Alger Management LLC acquired a new stake in Humana in the 4th quarter worth approximately $451,000. Institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on HUM. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a report on Thursday, May 1st. Raymond James Financial raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $315.00 target price for the company in a report on Thursday, May 1st. Truist Financial dropped their target price on shares of Humana from $280.00 to $260.00 and set a “hold” rating for the company in a report on Wednesday, July 16th. Bank of America dropped their target price on shares of Humana from $320.00 to $260.00 and set a “neutral” rating for the company in a report on Tuesday, June 17th. Finally, Mizuho upped their target price on shares of Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, April 9th. Sixteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and an average target price of $282.57.

Humana Stock Performance

Shares of HUM opened at $236.92 on Thursday. The firm has a market cap of $28.59 billion, a PE ratio of 16.76, a P/E/G ratio of 1.58 and a beta of 0.44. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The stock has a fifty day moving average price of $234.48 and a 200-day moving average price of $256.71. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $406.09.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $7.23 EPS. Equities research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.